{"id":7114,"date":"2024-03-27T12:45:00","date_gmt":"2024-03-27T11:45:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/"},"modified":"2024-03-27T12:45:00","modified_gmt":"2024-03-27T11:45:00","slug":"nanexa-publicerar-arsredovisning-for-2023","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/","title":{"rendered":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2023"},"content":{"rendered":"
\n

Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2023 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida <\/strong>www.nanexa.com\/finansiella-rapporter<\/a><\/strong>. <\/strong><\/p>\n

\u201dEtt \u00e5r som tagit oss n\u00e4rmare kommersialisering och den expansiva typ 2-diabetes- och obesitasmarknaden.\u201d<\/p>\n

\u201dUnder 2023 har vi levererat i v\u00e5ra produktprojekt och i de projekt vi driver tillsammans med ett antal ledande l\u00e4kemedelsbolag. Ett \u00e5r d\u00e4r vi skapat ytterligare resultat fr\u00e5n anv\u00e4ndningen av PharmaShell\u00ae som genererar intresse fr\u00e5n l\u00e4kemedelsbranschen. Mer kliniska data fr\u00e5n den genomf\u00f6rda studien i NEX-20 projektet och en stor m\u00e4ngd data fr\u00e5n olika prekliniska utv\u00e4rderingar adderar viktiga pusselbitar. Detta bland annat f\u00f6r att studera v\u00e4vnadsp\u00e5verkan vid injektionsst\u00e4llet, vilket \u00e4r mycket vanligt f\u00f6r injicerbara dep\u00e5beredningar och framf\u00f6r allt vid administrering av h\u00f6ga doser. Vi har ocks\u00e5 tr\u00e4ffat m\u00e5nga av v\u00e4rldens ledande l\u00e4kemedelsf\u00f6retag p\u00e5 konferenser som resulterat i ett stort intresse f\u00f6r Nanexa och PharmaShell som drug delivery-system. Dock \u00e4nnu inget nytt avg\u00f6rande avtal p\u00e5 plats under \u00e5ret. D\u00e4rf\u00f6r har vi beslutat att verkligen fokusera p\u00e5 de aktiviteter och projekt som vi bed\u00f6mer ligger n\u00e4rmast avtal som kan ge oss b\u00e5de st\u00f6rre int\u00e4kter i n\u00e4rtid och betydande licensint\u00e4kter i framtiden\u201d, s\u00e4ger David Westberg, vd p\u00e5 Nanexa.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa \u00c5rsredovisning 2023<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2023 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida www.nanexa.com\/finansiella-rapporter<\/a>. <\/p>\n

\u201dEtt \u00e5r som tagit oss n\u00e4rmare kommersialisering och den expansiva typ 2-diabetes- och obesitasmarknaden.\u201d<\/p>\n

\u201dUnder 2023 har vi levererat i v\u00e5ra produktprojekt och i de projekt vi driver tillsammans med ett antal ledande l\u00e4kemedelsbolag.<\/p>\n

L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-7114","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa publicerar \u00e5rsredovisning f\u00f6r 2023 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2023 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2023 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida www.nanexa.com\/finansiella-rapporter. \u201dEtt \u00e5r som tagit oss n\u00e4rmare kommersialisering och den expansiva typ 2-diabetes- och obesitasmarknaden.\u201d \u201dUnder 2023 har vi levererat i v\u00e5ra produktprojekt och i de projekt vi driver tillsammans med ett antal ledande l\u00e4kemedelsbolag.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2023\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2023\\\/\",\"name\":\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2023 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-03-27T11:45:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2023\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2023\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2023 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2023 - Nanexa AB","og_description":"Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2023 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida www.nanexa.com\/finansiella-rapporter. \u201dEtt \u00e5r som tagit oss n\u00e4rmare kommersialisering och den expansiva typ 2-diabetes- och obesitasmarknaden.\u201d \u201dUnder 2023 har vi levererat i v\u00e5ra produktprojekt och i de projekt vi driver tillsammans med ett antal ledande l\u00e4kemedelsbolag.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/","name":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2023 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-03-27T11:45:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2023"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}